Introduction
============

Thyroid nodules are a frequent pathology, with a lifetime occurrence risk in the general population estimated at 5--10% and a gender predilection since their prevalence is higher in women ([@b1-mmr-20-03-2332]). Furthermore, due to technological advancement and increased availability of high resolution ultrasound and other imaging modalities (e.g. incidental findings on carotid or heart ultrasound, or routine scans), in combination with the increased focus on preventive medicine and improved access to healthcare resources, their prevalence seems to be higher than estimated, with a recent study revealing thyroid nodules in about 19--68% of randomly selected individuals ([@b1-mmr-20-03-2332]).

In regards to treatment strategies, beyond surgery, several non-invasive procedures have been developed including, radiofrequency ablation, alcohol injection, high intensity-focused ultrasound, or laser ablation. A minimally invasive procedure was recently shown to be a safe and effective treatment for benign thyroid nodules: ablation with monopolar radiofrequency ([@b2-mmr-20-03-2332]). The last treatment approach is performed with a 16 or 18 Gauge internally cooled radiofrequency electrode after local anesthesia, which is able to treat autonomously functional nodules ([@b3-mmr-20-03-2332]). This leads to better results for smaller and cystic nodules; post-procedural complications are present only in 17% of patients ([@b2-mmr-20-03-2332]). Other studies have shown various results with mean decreases of 40--75% at 6 months ([@b4-mmr-20-03-2332],[@b5-mmr-20-03-2332]) and minimal complications in treating benign thyroid nodules with radiofrequency ablation ([@b5-mmr-20-03-2332],[@b6-mmr-20-03-2332]). Of note key success factors are technical skill and patient selection based on clinical evaluation ([@b7-mmr-20-03-2332]).

Even though the vast majority (around 95%) of thyroid nodules are benign ([@b1-mmr-20-03-2332],[@b8-mmr-20-03-2332]), and 5% remnant thyroid malignancies are among the most successfully treated endocrine cancers ([@b2-mmr-20-03-2332],[@b9-mmr-20-03-2332]), a novel, medical non-invasive treatment, which results in a decrease in the size of thyroid nodules would be beneficial.

Materials and methods
=====================

### Patients

Participants in this clinical study were consecutive patients who presented for initial evaluation or follow-up of thyroid nodules in the outpatient department of the National Institute of Endocrinology (Bucharest, Romania) during May-September 2018 and fulfilled the inclusion and exclusion criteria.

Inclusion criteria were: Adult patients \>18 years old; agreement to participate in the study by signing the informed consent form; euthyroid status \[normal thyroid stimulating hormone (TSH) and free thyroxine (fT4) values\], no active dysfunctional thyroid disease; benign thyroid nodule confirmed by FNAB (Bethesda 2); no previous thyroid surgery, thyroid ablation treatment, substitution treatment with thyroid hormones; no steroid or beta-blocker treatment; presence of one or more thyroid nodules documented by ultrasound.

Exclusion criteria were: pediatric patients (\<18 years old); diagnosis or suspicion of malignancy, including thyroid; autoimmune disease, including Hashimoto; Wilson\'s disease; hypo- or hyper-thyroidism; contraception with intrauterine device; acute infection; known allergy to spirulina, curcumin or *Boswellia*.

Thirty eight patients were enrolled and a total of 34 patients, 29 women and 5 men, completed the study. After being informed about the objective and requirements of the study (blood samples, ultrasound evaluations, supplement administration) with possible risks and benefits, the participants signed the informed consent form and were enrolled in the clinical study. Ethical rules established by the National Institute of Endocrinology CI Parhon according to the World Health Organisation guidelines were observed.

### Study design

A double-blind, placebo-controlled, cross-over clinical trial was performed to assess the efficacy of the spirulina-based supplement in decreasing the size of thyroid nodules. The study population consisted of 34 consecutive cases randomized initially to placebo (P) or active ingredients (AI).

There were three visits for each patient, noted as V1 - initial visit at enrollment; V2 - intermediary visit, 6 weeks post-administration of placebo (P) or active ingredients (AI); and V3 - final visit, after another 6 weeks of administration of P or AI. At each visit, each patient was tested for plasma TSH, fT4 and copper (Cu) levels, by an independent laboratory and a thyroid ultrasound was performed by an endocrinologist (DM) using the same ultrasound machine. The nodule images and dimensions were printed for comparison.

At V1, patients were randomly selected to receive either AI or P, so that half of them (n=17) received P and the other half (n=17) received AI. Subsequently at V2, the 17 patients previously on P received AI, and 12 of the 17 patients previously on AI received P, while the remaining 5 randomly chosen patients continued to receive AI. Consequently at V3, 17 patients received the sequence P-AI, 12 patients received AI-P, and 5 patients had AI-AI. The study was registered on [clinicaltrials.gov](clinicaltrials.gov) site with protocol ID 'TiroNod' and ID number NCT03535974, and titled: 'Efficacy of a spirulina supplement for Amelioration of benign thYroid nodules (ESSAY)'.

### Outcomes

The primary outcome of the study was a change in size of the thyroid nodules and this is usually evaluated through a comparison of the largest diameter of the nodules between measurements via ultrasound. However, we have observed that there are patients in which the largest diameter decreases while the smallest diameter increases, and this variability may lead to significant bias in comparisons. Therefore, for more consistent results and comparisons we calculated the product of the largest (D) and smallest (d) diameters of the nodules in the same incident angle (S = D × d) and compared the resulting area of the nodules measured at visits V1, 2, 3.

As secondary outcomes the serum levels of TSH, fT4 and Cu were assessed. The first two are considered standard evaluations of the thyroid function, while the latter was chosen for multiple reasons: i) spirulina is a significant source of Cu along with other minerals and vitamins; ii) most serum Cu is bound and transported by ceruloplasmin ([@b10-mmr-20-03-2332]), and iii) while there is an excellent correlation between serum Cu and ceruloplasmin, changes of Cu plasma levels are faster than plasma ceruloplasmin levels, thus serum Cu would provide more accurate information.

### Statistical analysis

NCSS 16 software was used for data analysis. Quantitative data were expressed as mean ± standard deviation (SD). Paired sample t-test was used for comparisons of two groups (AI and P). Pearson\'s correlation was used to assess correlations between specific variables. Wald Z test for proportions was used for comparing differences in outcomes between two groups. One-way ANOVA test with the Tukey and Bonferroni post-hoc was used to compare values of TSH, fT4 and Cu. α=0.05, and P\<0.05 indicated statistical significance.

### Treatment

The active treatment administered was a combination of spirulina, curcumin and *Boswellia* extracts, 400-50-50 mg per capsule, which were prepared alongside matching placebo capsules by DVR Pharm and BioNovative SRL. Patients were instructed to take two capsules twice daily, about 30 min before breakfast and lunch. Any adverse reactions were to be reported to the investigator.

Spirulina is the common generic name of about 15 species from two types of monocellular microalgae (Spirulina and *Arthrospira*), the most common being *Arthrospira* platensis ([@b11-mmr-20-03-2332]), which grows naturally in freshwater and saltwater on all continents and in most climates, optimally in an alkaline milieu (pH 9.5--12.0). It was used as the only source of nutrition in some areas in Africa for more than 1 month at a time and its first documented use was in China around 2,000 years ago even during periods of famine ([@b12-mmr-20-03-2332]). It has a very high protein content: 40--65% of dry mass depending on species and conditions of growth/cultivation ([@b13-mmr-20-03-2332]), and contains all essential amino acids, minerals (Fe, K, Na, Ca, P, I, Mg, Zn, Cu, Se, Mn, Cr) and vitamins (carotenoids 5 mg/g vitamins B1, B2, B3, B6, B12, folate, biotin, pantothenic acid, vit K1, K2), gamma linolenic acid, chlorophyll and phycocyanin, making it a complete food source. Alongside this remarkable composition it has important quantities of antioxidants, such as superoxide dysmutase (360 UI/g), zeaxanthin (3 mg/g), and vitamin E ([@b14-mmr-20-03-2332]).

Curcumin, a natural extract from the roots of *Curcuma longa*, has also been in use for centuries in Asia for various ailments. It is a potent anti-inflammatory substance with pleiotropic actions, including antioxidant and metabolic modulation. Its effects are well studied, with multiple clinical trials showing benefits in arthritis, inflammatory bowel disease, prediabetes, and even in early stages of neoplastic disease ([@b15-mmr-20-03-2332]). A recent meta-analysis on 15 randomized clinical trials shows that curcumin downregulates inflammation and oxidation products by reducing levels of IL-6, hs-CRP, and MDA ([@b16-mmr-20-03-2332]).

*Boswellia* is also a potent anti-inflammatory molecule, which blocks the NFkB pathway and modulates the activity of regulatory and effector T cells ([@b17-mmr-20-03-2332]). Together with curcumin it was shown to inhibit production of inflammatory cytokines Il-6, IL-8, TNF-α and reactive oxygen species ([@b18-mmr-20-03-2332],[@b19-mmr-20-03-2332]).

Results
=======

### Patients

A total of 38 patients were enrolled of whom 34 patients, 29 women and 5 men, aged 53.44±12.63 years, completed the study and were evaluated for the primary outcome - the size of the thyroid nodules evaluated by ultrasound at 1st (initial), 2nd (intermediate) and 3rd (final) patient visits. These 34 patients were also tested for serum TSH, fT4 and Cu.

The overall reduction in the measured surface of the thyroid nodules for all the 34 study participants, calculated as the mean percentage decrease in the surface of nodules, was 20.3%±19.18% (SD). For all 34 patients, mean initial nodule area at initial visit (V1 S) was 4.38±3.14 cm^2^; at 2nd visit (V2 S) mean nodule area and SD was: 3.87±2.79 cm^2^; and at 3rd visit (V3 S) mean nodule area and SD was 3.53±2.84 cm^2^.

### Thyroid nodule size and modifications

From the total of 34 patients who completed the 3 ultrasound evaluations, 29 patients (85.29%) had decreases in the areas of thyroid nodules of 5% or more at the end of the study, and 22 patients (64.7%) had decreases of 10% or more of the thyroid nodule area after 3 months.

One patient had insignificant decrease in nodule area (0.21%), and 4 patients had increases in the size of the nodules of 1.66, 2.36, 5.13 and 23.81%, respectively, at the final ultrasound assessment ([Table I](#tI-mmr-20-03-2332){ref-type="table"}).

Patients were also grouped according to the initial area of the nodules and their modifications at V2 and V3.

[Table II](#tII-mmr-20-03-2332){ref-type="table"} summarizes the modifications in nodule areas and shows an increase in the number of patients with nodule areas of \<6 cm^2^ at study visits 2 and 3 compared to V1 due to a gradual decrease in nodule areas. Patients with larger thyroid nodules (\>6 cm^2^) were the most dynamic group, their number decreasing from V1-V2-V3 to 11-7-5, respectively.

### Nodule size and visits

A graphic comparison of the effects of all patients at the three study visits is given in [Fig. 1](#f1-mmr-20-03-2332){ref-type="fig"}, which shows that the decrease of the mean areas of the nodules between the three visits were statistically significant: for V1 S vs. V2 S the paired sample t-test has P=0.00006; for V2 S vs. V3 S the paired sample t-test has P=0.04182; and for V1 S vs. V3 S paired sample t-test has P=0.00008.

A comparison of the effects of the active substance vs. placebo on decreasing the surface of thyroid nodules showed that after the initial administration of the placebo and active substances, the mean decrease with AI was 19.88±15.55%, while with the placebo the decrease was less, 9.31%±14.29%. The two-sided t-test for the two groups had a t value of 2.03, and the difference between placebo and active substances was marginally statistically significant (P=0.047).

Consequently, we used two additional statistical tests: the Wald Z test to compare the proportion of patients with modifications in nodule areas, grouped in AI vs. P and also tested both the equal variance and Aspin-Welch variants for the difference of means ± SD between the AI and P groups.

### Decrease in thyroid nodules area after active substances and placebo

The difference in the proportion of patients with decreased thyroid nodule areas on active substances vs. placebo groups was directly increased with each visit and the number of patients on AI vs. P; it achieved statistical significance at V3 vs. V1 (P=0.033); statistically significant results were obtained by comparing the mean ± SD of nodule areas in AI and P groups at V3-V1 (P=0.027) and V2-V1 (P=0.017), but not V3-V2 (P=0.16), probably because the AI effect was still present in patients taking P in the sequence AI-P ([Table III](#tIII-mmr-20-03-2332){ref-type="table"}).

Comparing the overall effects of the placebo and the active substances on all administrations (39 active substances, 29 placebo, total 68 sequences in 34 patients, [Fig. 2](#f2-mmr-20-03-2332){ref-type="fig"}), we have observed that the administration of the active substances (n=39) was followed by a mean decrease in nodule areas of 0.611 cm^2^±0.933 (SD), while placebo administration (n=29) was followed by a mean decrease of 0.178 cm^2^±0.515 (SD). Testing for statistical significance between the two groups (active and placebo) at V3 versus V1 with t-test for means and standard deviation, there was a mean difference of 0.433 cm^2^, which is statistically significant both when calculated with the equal variance t-test (standard error of the difference of 0.192, P=0.027) and the unequal variance Aspin-Welch test (standard error of the difference of 0.177, P=0.017) ([Table III](#tIII-mmr-20-03-2332){ref-type="table"}).

Based on these data it is evident that the active combination is effective in reducing the size of the thyroid nodules, even though it was administered for only 6 weeks out of the total of 3 months.

### Values of TSH, fT4 and Cu at the three visits

Beyond efficacy, we have also monitored the influence of treatment on thyroid function and the correlation with Cu levels. To determine whether the active substances or the placebo had a significant effect on thyroid function, we compared the respective values of TSH and fT4 for all 3 visits (visit 1 vs. 2, visit 1 vs. 3 and 2 vs. 3) with the one-way ANOVA test and the Tukey and Bonferroni post-hoc tests. There was no statistically significant difference between the respective values of TSH or fT4 in the initial, intermediary or final visits. A similar result was obtained when comparing the levels of serum Cu between the 3 visits; there were no significant differences between the respective values ([Table IV](#tIV-mmr-20-03-2332){ref-type="table"}).

To verify the interdependence of the four variables measured in this study: nodule surface, TSH, fT4 and Cu levels, we calculated the Pearson\'s correlation indices and found that the strongest correlation was between the decrease in nodules surface and TSH levels at visits 2 and 3: Δ S2-S3 and Δ TSH2 - TSH3, Pearson\'s correlation =0.52, P=0.002. There was also a significant inverse correlation of serum Cu and TSH modifications between the initial and final visits: Pearson\'s correlation of Δ Cu V1-V3 and Δ TSH V1-V3 was r=−0.3885; with P=0.033 (data not shown).

### Adverse effects

Four patients withdrew from the study before completion. Three of them reconsidered participation due to personal reasons, while one patient stopped one week post-administration of the study substances, because of development of a rash on the trunk and upper portions of limbs, while on multiple medications. Following investigation, it was revealed that the type of substance administered to the patient was the placebo.

No other adverse effects were recorded on the study participants for either the active substances or the placebo.

Discussion
==========

The link between thyroid function and ceruloplasmin, the most important Cu-based enzyme, was observed a few decades ago, with a significant elevation of serum ceruloplasmin being observed in patients on oral contraceptives together with an increase in thyroxine binding index, while free thyroxine levels were unchanged ([@b20-mmr-20-03-2332]). Similarly, in male rats estradiol elevated ceruloplasmin levels, while testosterone and thyroid hormones inhibited this action ([@b21-mmr-20-03-2332]). Furthermore, it was shown that administration of L-thyroxine suppresses the stimulation of ceruloplasmin by estrogen administration ([@b22-mmr-20-03-2332]). Opposite modifications of ceruloplasmin levels in hypo- and hyper-thyroid patients, in tandem with thyroid function, as well as oxidation status (malonyldialdehyde) and uric acid levels were observed by a Romanian team ([@b23-mmr-20-03-2332]). New direct links between ceruloplasmin, oxidative stress and inflammation were recently shown with TNF-related apoptosis-inducing ligand (TRAIL) down-regulating ceruloplasmin expression in inflammation ([@b24-mmr-20-03-2332]), and modulation of TNF-α-induced neutrophil apoptosis by ceruloplasmin ([@b25-mmr-20-03-2332]). Low levels of ceruloplasmin were shown in a hypothyroid patient with Hashimoto thyroiditis ([@b26-mmr-20-03-2332]).

Recent findings have shown that thyroid hormones increase serum Cu levels by stimulating the synthesis of ceruloplasmin in the liver as reflected in the mRNA levels, and this action is abolished in cases of hyperthyroidism associated with receptor resistance to thyroid hormones ([@b27-mmr-20-03-2332]). In addition, the ratio of serum Cu and selenium was proposed as an indirect marker for receptor resistance to thyroid hormones. Stimulation of hepatic ceruloplasmin mRNA by thyroxine and dexamethasone was previously shown in rats ([@b28-mmr-20-03-2332]). It was also found that a Cu-deficient diet increases the levels of serum free triiodothyronine but not fT4 in rats ([@b29-mmr-20-03-2332]); similarly a strong link between serum T3 and Cu was demonstrated in rat pups ([@b30-mmr-20-03-2332]). Cu and Zn levels in serum and tissue are modulated by thyroid hormones as shown by thyro-parathyroidectomy and T4 replacement in rat. Interestingly, it was seen that ceruloplasmin is present in follicular carcinoma and absent in adenomas ([@b31-mmr-20-03-2332]--[@b33-mmr-20-03-2332]). Further differences in the oxidative and inflammatory processes involved in benign and malignant thyroid nodules versus normal thyroid tissue (hypoxia-inducible factor-1, complement factor D, matrix metalloprotease 1, Von Willebrand Factor - were shown in different studies ([@b34-mmr-20-03-2332]) The interrelations between thyroid hormones, ceruloplasmin, adrenal hormones and important metabolic processes are presented in [Fig. 3](#f3-mmr-20-03-2332){ref-type="fig"}.

Before administration of the indicated spirulina-curcumin-*Boswellia* combination, a thorough evaluation by an DM (with or without a thyroid ultrasound) should be performed, in order to establish euthyroid status, exclude patients with suspicion of malignancy, acute infection, autoimmune disease, Wilson\'s disease, and monitor possible associations with contraceptives or other simultaneous medical treatments.

In summary, the combination of spirulina-curcumin-*Boswellia* is effective in reducing the size of benign thyroid nodules and can be safely administered in the doses used in the presented clinical study. The mechanism by which the decrease of the nodule size is facilitated, is probably linked to the anti-inflammatory effects, the improvement of the antioxidant status and the ceruloplasmin actions. However, additional studies are needed in order to elucidate these associations, which may also provide important insights into the pathogenesis of thyroid nodules.
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![Nodule size at V1, V2, V3 in all patients. In all 34 patients, the mean initial nodule area at initial visit (V1 S) was 4.38±3.14 cm^2^, at 2nd visit (V2 S) mean nodule area and SD was: 3.87±2.79 cm^2^, and at 3nd visit (V3 S) mean nodule area and SD was 3.53±2.84 cm^2^. D, large diameter; d, small diameter; S, area; SD, standard deviation.](MMR-20-03-2332-g00){#f1-mmr-20-03-2332}

![The figure graphically represents the significant data from [Table III](#tIII-mmr-20-03-2332){ref-type="table"}, comparing the means, min and max values nodule areas in the AI (Act) and P (Plac) groups after the initial 6 week administration of AI or P (V2-V1, noted 'A') and after 12 weeks of AI or P (V3-V1, noted 'A+B', A being the initial 6 weeks, B the final 6 weeks of study). As noted in [Table III](#tIII-mmr-20-03-2332){ref-type="table"}, in the 'B' period of the study (V3-V2) the mean nodule areas in the AI vs. P groups were not statistically significant. A Act, A Plac (n=17), A+B Act (n=39), A+B Plac (n=29).](MMR-20-03-2332-g01){#f2-mmr-20-03-2332}

![Interactions between thyroid hormones, ceruloplasmin, adrenal hormones, and processes of intestinal absorbtion, oxidative metabolism and inflammation. T3/T4, triiodothyronine/thyroxine; TRH/TSH, thyroid releasing/stimulating hormones; ACTH, adrenocorticotropic hormone; SOD, superoxide dysmutase.](MMR-20-03-2332-g02){#f3-mmr-20-03-2332}

###### 

Percentage change from initial vs. final area of thyroid nodules.

  Initial vs. final area decrease %   \<0 (increase)   \~0 (unchanged)   5--9.9% (decrease)   10--19.9% (decrease)   20--49.9% (decrease)   50-99% (decrease)
  ----------------------------------- ---------------- ----------------- -------------------- ---------------------- ---------------------- -------------------
  No. of patients                     4                1                 7                    7                      12                     3

###### 

Number of patients at V1, V2, V3, grouped by nodule area.

  Initial nodule surface / no. of patients   0.1--0.99 cm^2^   1--2.99 cm^2^   3--5.99 cm^2^   6--8.99 cm^2^   \>9 cm^2^
  ------------------------------------------ ----------------- --------------- --------------- --------------- -----------
  Visit 1                                    4                 10              9               8               3
  Visit 2                                    5                 10              12              5               2
  Visit 3                                    6                 9               14              3               2

###### 

Decrease in thyroid nodules area after active substances and placebo.

  Mean ± SD decrease      Active substance   Placebo       Statistical significance                                  Total active + placebo
  ----------------------- ------------------ ------------- --------------------------------------------------------- ------------------------
  V2 - V1, cm^2^          0.784±0.708        0.238±0.444   P=0.017^[a](#tfn1-mmr-20-03-2332){ref-type="table-fn"}^   0.511±0.645
  V3 - V2, cm^2^          0.499±1.069        0.094±0.612   P=0.16^[a](#tfn1-mmr-20-03-2332){ref-type="table-fn"}^    0.343±0.944
  V3 - V1, cm^2^          0.611±0.933        0.178±0.515   P=0.027^[a](#tfn1-mmr-20-03-2332){ref-type="table-fn"}^   0.854±1.108
  Patients nb V2 vs. V1   16/17              13/17         P=0.14^[b](#tfn2-mmr-20-03-2332){ref-type="table-fn"}^      29/34
  Patients nb V3 vs. V2   18/22              6/12          P=0.051^[b](#tfn2-mmr-20-03-2332){ref-type="table-fn"}^   23/34
  Patients nb V3 vs. V1   34/39              19/29         P=0.033^[b](#tfn2-mmr-20-03-2332){ref-type="table-fn"}^   30/34

Test for difference of means and standard deviation (equal variance and Aspin-Welch)

two-sided Wald Z test; SD, standrad deviation.

###### 

Values of TSH, fT4 and Cu at the three visits, and ANOVA test values.

  Visit and test type   V1 TSH                     V2 TSH                     V3 TSH                     V1 fT4   V2 fT4   V3 fT4   V1 Cu    V2 Cu    V3Cu
  --------------------- -------------------------- -------------------------- -------------------------- -------- -------- -------- -------- -------- --------
  Number tested         34                         34                         32                         33       34       32       33       33       31
  Mean                  1.50                       1.37                       1.30                       1.18     1.18     1.196    127.65   127.13   128.38
  SD                    1.27                       1.11                       0.96                       0.17     0.17     0.16     21.55    21.34    16.26
  ANOVA V1-V2-V3        F-ratio =0.28472, P=0.75   F-ratio =0.06792, P=0.93   F-ratio =0.03162, P=0.96                                                

TSH, thyroid stimulating hormone; fT4, free thyroxine; Cu, copper.
